17 results on '"Wages, Nolan A."'
Search Results
2. Change in parathyroid hormone levels from baseline predicts hypocalcemia following total or completion thyroidectomy.
- Author
-
Swift, William M., Iorio, Caitlin B., Hamdi, Osama A., Mallawaarachchi, Indika, Wages, Nolan A., and Shonka, David C.
- Subjects
HYPOCALCEMIA ,PARATHYROID hormone ,THYROIDECTOMY ,MULTIVARIATE analysis - Abstract
Background: This study aims to identify the strongest predictor of postoperative hypocalcemia following thyroid surgery. Methods: Study of patients who underwent total/completion thyroidectomy. No patients received postoperative calcium supplementation. Demographic and perioperative data were collected including preoperative baseline parathyroid hormone (PTH) levels, PTH levels at 30 min and 6 h post‐excision, and 18 h post‐excision calcium levels. Results: Of 124 patients studied, 20.2% developed temporary hypocalcemia (Ca <8.5 mg/dL at 18 h post‐excision). In multivariate analyses, absolute PTH levels at 30 min and 6 h post‐excision as well as change in PTH from baseline at 30 min and 6 h post‐excision were statistically significantly associated with postoperative hypocalcemia. Per 10 units decrease in PTH from baseline at 30 min post‐excision, the risk of developing temporary hypocalcemia increases by 17%. Conclusion: Absolute PTH levels and change in PTH from baseline at 30 min and 6 h post‐excision predict hypocalcemia after total or completion thyroidectomy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Coherence principles in interval‐based dose finding.
- Author
-
Wages, Nolan A., Iasonos, Alexia, O'Quigley, John, and Conaway, Mark R.
- Subjects
- *
DECISION making - Abstract
This paper studies the notion of coherence in interval‐based dose‐finding methods. An incoherent decision is either (a) a recommendation to escalate the dose following an observed dose‐limiting toxicity or (b) a recommendation to deescalate the dose following a non–dose‐limiting toxicity. In a simulated example, we illustrate that the Bayesian optimal interval method and the Keyboard method are not coherent. We generated dose‐limiting toxicity outcomes under an assumed set of true probabilities for a trial of n=36 patients in cohorts of size 1, and we counted the number of incoherent dosing decisions that were made throughout this simulated trial. Each of the methods studied resulted in 13/36 (36%) incoherent decisions in the simulated trial. Additionally, for two different target dose‐limiting toxicity rates, 20% and 30%, and a sample size of n=30 patients, we randomly generated 100 dose‐toxicity curves and tabulated the number of incoherent decisions made by each method in 1000 simulated trials under each curve. For each method studied, the probability of incurring at least one incoherent decision during the conduct of a single trial is greater than 75%. Coherency is an important principle in the conduct of dose‐finding trials. Interval‐based methods violate this principle for cohorts of size 1 and require additional modifications to overcome this shortcoming. Researchers need to take a closer look at the dose assignment behavior of interval‐based methods when using them to plan dose‐finding studies. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Identifying a maximum tolerated contour in two-dimensional dose finding.
- Author
-
Wages, Nolan A.
- Subjects
- *
ANTINEOPLASTIC agents , *CLINICAL trials , *COMPUTER simulation , *COMPUTER software , *DRUG dosage , *DRUG toxicity , *PROBABILITY theory , *RESEARCH funding , *STATISTICS , *TUMORS , *STATISTICAL models - Abstract
The majority of phase I methods for multi-agent trials have focused on identifying a single maximum tolerated dose combination (MTDC) among those being investigated. Some published methods in the area have been based on the notion that there is no unique MTDC and that the set of dose combinations with acceptable toxicity forms an equivalence contour in two dimensions. Therefore, it may be of interest to find multiple MTDCs for further testing for efficacy in a phase II setting. In this paper, we present a new dose-finding method that extends the continual reassessment method to account for the location of multiple MTDCs. Operating characteristics are demonstrated through simulation studies and are compared with existing methodology. Some brief discussion of implementation and available software is also provided. Copyright © 2016 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. Implementation of adaptive methods in early-phase clinical trials.
- Author
-
Petroni, Gina R., Wages, Nolan A., Paux, Gautier, and Dubois, Frédéric
- Subjects
- *
ALGORITHMS , *CLINICAL trials , *COMPUTER simulation , *COMPUTER software , *DECISION making , *DRUG dosage , *DOSE-effect relationship in pharmacology , *DRUG side effects , *DRUG toxicity , *LONGITUDINAL method , *MEDICAL protocols , *SAFETY , *STATISTICS , *SAMPLE size (Statistics) - Abstract
There has been constant development of novel statistical methods in the design of early-phase clinical trials since the introduction of model-based designs, yet the traditional or modified 3+3 algorithmic design remains the most widely used approach in dose-finding studies. Research has shown the limitations of this traditional design compared with more innovative approaches yet the use of these model-based designs remains infrequent. This can be attributed to several causes including a poor understanding from clinicians and reviewers into how the designs work, and how best to evaluate the appropriateness of a proposed design. These barriers are likely to be enhanced in the coming years as the recent paradigm of drug development involves a shift to more complex dose-finding problems. This article reviews relevant information that should be included in clinical trial protocols to aid in the acceptance and approval of novel methods. We provide practical guidance for implementing these efficient designs with the aim of augmenting a broader transition from algorithmic to adaptive model-guided designs. In addition we highlight issues to consider in the actual implementation of a trial once approval is obtained. Copyright © 2016 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
- Author
-
Horton, Bethany Jablonski, Wages, Nolan A., and Conaway, Mark R.
- Subjects
- *
ALGORITHMS , *CLINICAL trials , *COMPUTER simulation , *DRUG dosage , *DOSE-effect relationship in pharmacology , *DRUG side effects , *DRUG toxicity , *PROBABILITY theory , *RESEARCH funding , *STATISTICS , *STATISTICAL models - Abstract
Toxicity probability interval designs have received increasing attention as a dose-finding method in recent years. In this study, we compared the two-stage, likelihood-based continual reassessment method (CRM), modified toxicity probability interval (mTPI), and the Bayesian optimal interval design (BOIN) in order to evaluate each method's performance in dose selection for phase I trials. We use several summary measures to compare the performance of these methods, including percentage of correct selection (PCS) of the true maximum tolerable dose (MTD), allocation of patients to doses at and around the true MTD, and an accuracy index. This index is an efficiency measure that describes the entire distribution of MTD selection and patient allocation by taking into account the distance between the true probability of toxicity at each dose level and the target toxicity rate. The simulation study considered a broad range of toxicity curves and various sample sizes. When considering PCS, we found that CRM outperformed the two competing methods in most scenarios, followed by BOIN, then mTPI. We observed a similar trend when considering the accuracy index for dose allocation, where CRM most often outperformed both mTPI and BOIN. These trends were more pronounced with increasing number of dose levels. Copyright © 2016 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Designs for phase I trials in ordered groups.
- Author
-
Conaway, Mark R. and Wages, Nolan A.
- Subjects
- *
ALGORITHMS , *ANTINEOPLASTIC agents , *CLINICAL trials , *COMPUTER simulation , *DRUG dosage , *DOSE-effect relationship in pharmacology , *DRUG toxicity , *RESEARCH funding , *STATISTICS , *TUMORS , *STATISTICAL models - Abstract
We propose a new design for dose finding for cytotoxic agents in two ordered groups of patients. By ordered groups, we mean that prior to the study there is clinical information that would indicate that for a given dose one group would be more susceptible to toxicities than patients in the other group. The designs are evaluated relative to two previously proposed designs for ordered groups over a range of scenarios generated randomly from a family of dose-toxicity curves. Copyright © 2016 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
8. Dimension of model parameter space and operating characteristics in adaptive dose-finding studies.
- Author
-
Iasonos, Alexia, Wages, Nolan A., Conaway, Mark R., Cheung, Ken, Yuan, Ying, and O'Quigley, John
- Subjects
- *
CLINICAL trials , *DRUG dosage , *DOSE-effect relationship in pharmacology , *DRUG toxicity , *RESEARCH funding , *STATISTICAL models - Abstract
Adaptive, model-based, dose-finding methods, such as the continual reassessment method, have been shown to have good operating characteristics. One school of thought argues in favor of the use of parsimonious models, not modeling all aspects of the problem, and using a strict minimum number of parameters. In particular, for the standard situation of a single homogeneous group, it is common to appeal to a one-parameter model. Other authors argue for a more classical approach that models all aspects of the problem. Here, we show that increasing the dimension of the parameter space, in the context of adaptive dose-finding studies, is usually counter productive and, rather than leading to improvements in operating characteristics, the added dimensionality is likely to result in difficulties. Among these are inconsistency of parameter estimates, lack of coherence in escalation or de-escalation, erratic behavior, getting stuck at the wrong level, and, in almost all cases, poorer performance in terms of correct identification of the targeted dose. Our conclusions are based on both theoretical results and simulations. Copyright © 2016 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.
- Author
-
Hirakawa, Akihiro, Wages, Nolan A., Sato, Hiroyuki, and Matsui, Shigeyuki
- Abstract
Little is known about the relative performance of competing model-based dose-finding methods for combination phase I trials. In this study, we focused on five model-based dose-finding methods that have been recently developed. We compared the recommendation rates for true maximum-tolerated dose combinations (MTDCs) and over-dose combinations among these methods under 16 scenarios for 3 × 3, 4 × 4, 2 × 4, and 3 × 5 dose combination matrices. We found that performance of the model-based dose-finding methods varied depending on (1) whether the dose combination matrix is square or not; (2) whether the true MTDCs exist within the same group along the diagonals of the dose combination matrix; and (3) the number of true MTDCs. We discuss the details of the operating characteristics and the advantages and disadvantages of the five methods compared. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial.
- Author
-
Wages, Nolan A., Read, Paul W., and Petroni, Gina R.
- Subjects
- *
DRUG dosage , *PHARMACEUTICAL arithmetic , *STEREOTACTIC radiotherapy , *RADIOTHERAPY , *CLINICAL trials , *ONCOLOGY - Abstract
Dose-finding studies that aim to evaluate the safety of single agents are becoming less common, and advances in clinical research have complicated the paradigm of dose finding in oncology. A class of more complex problems, such as targeted agents, combination therapies and stratification of patients by clinical or genetic characteristics, has created the need to adapt early-phase trial design to the specific type of drug being investigated and the corresponding endpoints. In this article, we describe the implementation of an adaptive design based on a continual reassessment method for heterogeneous groups, modified to coincide with the objectives of a Phase I/II trial of stereotactic body radiation therapy in patients with painful osseous metastatic disease. Operating characteristics of the Institutional Review Board approved design are demonstrated under various possible true scenarios via simulation studies. Copyright © 2015 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
11. Comments on 'Competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, S. Zohar.
- Author
-
Wages, Nolan A.
- Published
- 2015
- Full Text
- View/download PDF
12. Phase I/II adaptive design for drug combination oncology trials.
- Author
-
Wages, Nolan A. and Conaway, Mark R.
- Abstract
Existing statistical methodology on dose finding for combination chemotherapies has focused on toxicity considerations alone in finding a maximum tolerated dose combination to recommend for further testing of efficacy in a phase II setting. Recently, there has been increasing interest in integrating phase I and phase II trials in order to facilitate drug development. In this article, we propose a new adaptive phase I/II method for dual-agent combinations that takes into account both toxicity and efficacy after each cohort inclusion. The primary objective, both within and at the conclusion of the trial, becomes finding a single dose combination with an acceptable level of toxicity that maximizes efficacious response. We assume that there exist monotone dose-toxicity and dose-efficacy relationships among doses of one agent when the dose of other agent is fixed. We perform extensive simulation studies that demonstrate the operating characteristics of our proposed approach, and we compare simulated results to existing methodology in phase I/II design for combinations of agents. Copyright © 2014 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. Phase I design for completely or partially ordered treatment schedules.
- Author
-
Wages, Nolan A., O'Quigley, John, and Conaway, Mark R.
- Abstract
The majority of methods for the design of phase I trials in oncology are based upon a single course of therapy, yet in actual practice, it may be the case that there is more than one treatment schedule for any given dose. Therefore, the probability of observing a dose-limiting toxicity may depend upon both the total amount of the dose given, as well as the frequency with which it is administered. The objective of the study then becomes to find an acceptable combination of both dose and schedule. Past literature on designing these trials has entailed the assumption that toxicity increases monotonically with both dose and schedule. In this article, we relax this assumption for schedules and present a dose-schedule finding design that can be generalized to situations in which we know the ordering between all schedules and those in which we do not. We present simulation results that compare our method with other suggested dose-schedule finding methodology. Copyright © 2013 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
14. Specifications of a continual reassessment method design for phase I trials of combined drugs Specifications of a continual reassessment method design for phase I trials of combined drugs.
- Author
-
Wages, Nolan A. and Conaway, Mark R.
- Subjects
- *
MEDICAL research , *CLINICAL trials , *ONCOLOGY research , *TOXICITY testing - Abstract
In studies of combinations of agents in phase I oncology trials, the dose-toxicity relationship may not be monotone for all combinations, in which case the toxicity probabilities follow a partial order. The continual reassessment method for partial orders (PO-CRM) is a design for phase I trials of combinations that leans upon identifying possible complete orders associated with the partial order. This article addresses some practical design considerations not previously undertaken when describing the PO-CRM. We describe an approach in choosing a proper subset of possible orderings, formulated according to the known toxicity relationships within a matrix of combination therapies. Other design issues, such as working model selection and stopping rules, are also discussed. We demonstrate the practical ability of PO-CRM as a phase I design for combinations through its use in a recent trial designed at the University of Virginia Cancer Center. Copyright © 2013 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
15. Using the time-to-event continual reassessment method in the presence of partial orders.
- Author
-
Wages, Nolan A., Conaway, Mark R., and O'Quigley, John
- Abstract
The time-to-event continual reassessment method (TITE-CRM) was proposed to handle the problem of long trial duration in Phase 1 trials as a result of late-onset toxicities. Here, we implement the TITE-CRM in dose-finding trials of combinations of agents. When studying multiple agents, monotonicity of the dose-toxicity curve is not clearly defined. Therefore, the toxicity probabilities follow a partial order, meaning that there are pairs of treatments for which the ordering of the toxicity probabilities is not known at the start of the trial. A CRM design for partially ordered trials (PO-CRM) was recently proposed. Simulation studies show that extending the TITE-CRM to the partial order setting produces results similar to those of the PO-CRM in terms of maximum tolerated dose recommendation yet reduces the duration of the trial. Copyright © 2012 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
16. Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia.
- Author
-
Murray, Graeme F., Bouligny, Ian M., Ho, Thuy, Gor, Juhi, Zacholski, Kyle, Wages, Nolan A., Grant, Steven, and Maher, Keri R.
- Subjects
- *
ACUTE myeloid leukemia , *CHROMOSOME abnormalities , *OVERALL survival , *DISEASE relapse , *PHYSICIANS - Abstract
ABSTRACT Clonal evolution (CE) is a driving force behind the development and progression of acute myeloid leukemia (AML). Advances in molecular and cytogenetic assays have improved the depth and breadth of detection of CE in AML, which is defined here as a detected change in cytogenetic or molecular profile at relapsed or refractory (RR) disease. In this study, we demonstrate the clinical impact of CE in a cohort of patients with RR AML treated between 2013 and 2023. We discovered CE is significantly more frequent in relapsed disease (58.2%, [46.6%, 69.2%]) than in refractory disease (21.1%, [14.4%, 29.2%], p < 0.001). CE negatively impacts prognosis when detected by conventional karyotyping in refractory disease (4.2 vs. 13.9 months, p < 0.011). In contrast with prior literature, CE had no impact on overall survival if detected in relapsed disease. Surprisingly, those who achieved negative measurable residual disease (MRD) were no more likely to eliminate their original clone than those who did not (p = 1). We found several cytogenetic and molecular signatures which may predispose to CE: aberrations of chromosome 17, trisomy 8, TP53, KRAS, and FLT3‐TKD. Finally, physicians were less likely to retreat those with CE with IC after receiving IC as first‐line therapy (35.0% vs. 70.9%, p = 0.004). This study illustrates the role of CE in chemotherapy‐resistant AML; we identify unique cytogenetic and molecular signatures that define a subset of patients associated with a dismal prognosis. As next‐generation sequencing panels expand and new methods to characterize cytogenetic abnormalities emerge, our findings establish a basis for future studies investigating the prognostic and therapeutic impact of CE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Comments on 'A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials' by Akihiro Hirakawa, Chikuma Hamada, and Shigeyuki Matsui.
- Author
-
Wages, Nolan A., Conaway, Mark R., and O’Quigley, John
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.